

Daniel Ricklin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/545563/publications.pdf>

Version: 2024-02-01

128
papers

12,818
citations

44069
48
h-index

24258
110
g-index

149
all docs

149
docs citations

149
times ranked

12386
citing authors

#	ARTICLE	IF	CITATIONS
1	From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors. Clinical Immunology, 2022, 235, 108785.	3.2	30
2	Selective Monovalent Galectin-8 Ligands Based on 3- α -Lactoylgalactoside. ChemMedChem, 2022, 17, .	3.2	4
3	Compstatins: the dawn of clinical C3-targeted complement inhibition. Trends in Pharmacological Sciences, 2022, 43, 629-640.	8.7	31
4	Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces. Frontiers in Immunology, 2021, 12, 615748.	4.8	9
5	The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology. Frontiers in Immunology, 2021, 12, 662164.	4.8	40
6	C1q binding to surface-bound IgG is stabilized by C1r ₂ s ₂ proteases. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	32
7	Tipping the balance: intricate roles of the complement system in disease and therapy. Seminars in Immunopathology, 2021, 43, 757-771.	6.1	59
8	Complement & disease: out of the shadow into the spotlight. Seminars in Immunopathology, 2021, 43, 755-756.	6.1	3
9	Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells. Haematologica, 2020, 105, e57-e60.	3.5	17
10	A Potent Mimetic of the Siglec-8 Ligand 6- α -Sulfo- α -Sialyl Lewis ^x . ChemMedChem, 2020, 15, 1706-1719.	3.2	11
11	Intracellular C4BPA Levels Regulate NF- κ B-Dependent Apoptosis. IScience, 2020, 23, 101594.	4.1	10
12	Sweet turning bitter: Carbohydrate sensing of complement in host defence and disease. British Journal of Pharmacology, 2020, 178, 2802-2822.	5.4	4
13	Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. Clinical Immunology, 2020, 214, 108391.	3.2	16
14	Clinical promise of next-generation complement therapeutics. Nature Reviews Drug Discovery, 2019, 18, 707-729.	46.4	253
15	“Stealth” corporate innovation: an emerging threat for therapeutic drug development. Nature Immunology, 2019, 20, 1409-1413.	14.5	7
16	Therapeutic targeting of the complement system. Nature Reviews Drug Discovery, 2019, , .	46.4	37
17	Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. Haematologica, 2019, 104, 919-928.	3.5	34
18	Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock. Shock, 2019, 51, 78-87.	2.1	34

#	ARTICLE	IF	CITATIONS
19	Complement in cancer: untangling an intricate relationship. <i>Nature Reviews Immunology</i> , 2018, 18, 5-18.	22.7	279
20	Native state of complement protein C3d analysed via hydrogen exchange and conformational sampling. <i>International Journal of Computational Biology and Drug Design</i> , 2018, 11, 90.	0.3	6
21	Developments in anti-complement therapy; from disease to clinical trial. <i>Molecular Immunology</i> , 2018, 102, 89-119.	2.2	72
22	The renaissance of complement therapeutics. <i>Nature Reviews Nephrology</i> , 2018, 14, 26-47.	9.6	305
23	Structural Implications for the Formation and Function of the Complement Effector Protein iC3b. <i>Journal of Immunology</i> , 2017, 198, 3326-3335.	0.8	21
24	Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. <i>Trends in Immunology</i> , 2017, 38, 383-394.	6.8	31
25	Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. <i>Molecular Immunology</i> , 2017, 89, 10-21.	2.2	79
26	Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. <i>Blood</i> , 2017, 129, 970-980.	1.4	119
27	Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 367-378.	4.2	12
28	Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1041-1042, 19-26.	2.3	8
29	Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10948-10953.	7.1	77
30	Novel mechanisms and functions of complement. <i>Nature Immunology</i> , 2017, 18, 1288-1298.	14.5	364
31	Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. <i>Nature Structural and Molecular Biology</i> , 2017, 24, 643-651.	8.2	106
32	Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation. <i>Frontiers in Immunology</i> , 2017, 8, 1586.	4.8	14
33	Coarse-Grained Conformational Sampling of Protein Structure Improves the Fit to Experimental Hydrogen-Exchange Data. <i>Frontiers in Molecular Biosciences</i> , 2017, 4, 13.	3.5	28
34	From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. <i>Immunobiology</i> , 2016, 221, 1046-1057.	1.9	14
35	Regulators of complement activity mediate inhibitory mechanisms through a common C3bâ€binding mode. <i>EMBO Journal</i> , 2016, 35, 1133-1149.	7.8	123
36	Complement in disease: a defence system turning offensive. <i>Nature Reviews Nephrology</i> , 2016, 12, 383-401.	9.6	427

#	ARTICLE	IF	CITATIONS
37	Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. <i>Seminars in Immunology</i> , 2016, 28, 285-291.	5.6	44
38	Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. <i>Clinical Immunology</i> , 2016, 171, 32-35.	3.2	23
39	Complement therapeutics. <i>Seminars in Immunology</i> , 2016, 28, 205-207.	5.6	12
40	Protection of host cells by complement regulators. <i>Immunological Reviews</i> , 2016, 274, 152-171.	6.0	173
41	Preformed mediators of defense—Gatekeepers enter the spotlight. <i>Immunological Reviews</i> , 2016, 274, 5-8.	6.0	4
42	Complement component C3 — The “Swiss Army Knife” of innate immunity and host defense. <i>Immunological Reviews</i> , 2016, 274, 33-58.	6.0	313
43	Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. <i>Journal of Clinical Periodontology</i> , 2016, 43, 238-249.	4.9	55
44	New milestones ahead in complement-targeted therapy. <i>Seminars in Immunology</i> , 2016, 28, 208-222.	5.6	92
45	Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood. <i>Journal of Immunology</i> , 2016, 196, 4671-4680.	0.8	35
46	Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. <i>Clinical Immunology</i> , 2016, 162, 37-44.	3.2	14
47	Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation. <i>Journal of Immunology</i> , 2016, 196, 866-876.	0.8	37
48	Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. <i>Molecular Oral Microbiology</i> , 2016, 31, 3-17.	2.7	36
49	Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. <i>Immunobiology</i> , 2016, 221, 503-511.	1.9	28
50	Therapeutic control of complement activation at the level of the central component C3. <i>Immunobiology</i> , 2016, 221, 740-746.	1.9	41
51	Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1207-1217.	3.4	38
52	Complement Deficiency Promotes Cutaneous Wound Healing in Mice. <i>Journal of Immunology</i> , 2015, 194, 1285-1291.	0.8	58
53	Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. <i>Immunobiology</i> , 2015, 220, 993-998.	1.9	49
54	Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2015, 126, 891-894.	1.4	89

#	ARTICLE	IF	CITATIONS
55	Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. <i>Immunobiology</i> , 2015, 220, 476-482.	1.9	58
56	Rare Loss-of-Function Mutation in Complement Component C3 Provides Insight into Molecular and Pathophysiological Determinants of Complement Activity. <i>Journal of Immunology</i> , 2015, 194, 3305-3316.	0.8	23
57	Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. <i>European Journal of Clinical Investigation</i> , 2015, 45, 423-440.	3.4	178
58	Applying complement therapeutics to rare diseases. <i>Clinical Immunology</i> , 2015, 161, 225-240.	3.2	60
59	Attenuation of <i>Staphylococcus aureus</i> -Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb. <i>Journal of Immunology</i> , 2015, 195, 3946-3958.	0.8	9
60	The Extracellular Adherence Protein from <i>Staphylococcus aureus</i> Inhibits the Classical and Lectin Pathways of Complement by Blocking Formation of the C3 Proconvertase. <i>Journal of Immunology</i> , 2014, 193, 6161-6171.	0.8	51
61	Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. <i>Expert Review of Hematology</i> , 2014, 7, 583-598.	2.2	43
62	Conjugation to Albumin-Binding Molecule Tags as a Strategy to Improve Both Efficacy and Pharmacokinetic Properties of the Complement Inhibitor Compstatin. <i>ChemMedChem</i> , 2014, 9, 2223-2226.	3.2	13
63	Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. <i>Biomaterials</i> , 2014, 35, 3688-3696.	11.4	40
64	Genetic and Intervention Studies Implicating Complement C3 as a Major Target for the Treatment of Periodontitis. <i>Journal of Immunology</i> , 2014, 192, 6020-6027.	0.8	97
65	Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2014, 123, 2094-2101.	1.4	172
66	Inhibition of biomaterial-induced complement activation attenuates the inflammatory host response to implantation. <i>FASEB Journal</i> , 2013, 27, 2768-2776.	0.5	35
67	CMAPI: Complement Map Database. <i>Bioinformatics</i> , 2013, 29, 1832-1833.	4.1	26
68	Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms. <i>Journal of Immunology</i> , 2013, 190, 3831-3838.	0.8	412
69	Complement in Immune and Inflammatory Disorders: Therapeutic Interventions. <i>Journal of Immunology</i> , 2013, 190, 3839-3847.	0.8	209
70	Progress and Trends in Complement Therapeutics. <i>Advances in Experimental Medicine and Biology</i> , 2013, 735, 1-22.	1.6	107
71	New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. <i>Immunobiology</i> , 2013, 218, 496-505.	1.9	129
72	Complement in Action: An Analysis of Patent Trends from 1976 Through 2011. <i>Advances in Experimental Medicine and Biology</i> , 2013, 735, 301-313.	1.6	9

#	ARTICLE	IF	CITATIONS
73	Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. <i>Biomaterials</i> , 2013, 34, 985-994.	11.4	50
74	Induction of Complement C3a Receptor Responses by Kallikrein-Related Peptidase 14. <i>Journal of Immunology</i> , 2013, 191, 3858-3866.	0.8	24
75	A Structurally Dynamic N-terminal Helix Is a Key Functional Determinant in Staphylococcal Complement Inhibitor (SCIN) Proteins. <i>Journal of Biological Chemistry</i> , 2013, 288, 2870-2881.	3.4	16
76	Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting Properties. <i>Journal of Immunology</i> , 2013, 190, 5712-5721.	0.8	137
77	TMA: beware of complements. <i>Blood</i> , 2013, 122, 1997-1999.	1.4	21
78	Progress and trends in complement therapeutics. <i>Advances in Experimental Medicine and Biology</i> , 2013, 735, 1-22.	1.6	11
79	A sweet spot to control complement-induced inflammation. <i>Nature Medicine</i> , 2012, 18, 1340-1341.	30.7	6
80	C5a Receptor-Dependent Cell Activation by Physiological Concentrations of Desarginated C5a: Insights from a Novel Label-Free Cellular Assay. <i>Journal of Immunology</i> , 2012, 189, 4797-4805.	0.8	50
81	Correction: Protection of nonself surfaces from complement attack by factor h-binding peptides: implications for therapeutic medicine. <i>Journal of Immunology</i> , 2012, 188, 6425-6425.	0.8	2
82	Diversity in the C3b contact residues and tertiary structures of the staphylococcal complement inhibitor (SCIN) protein family.. <i>Journal of Biological Chemistry</i> , 2012, 287, 9329.	3.4	0
83	Diversity in the C3b Convertase Contact Residues and Tertiary Structures of the Staphylococcal Complement Inhibitor (SCIN) Protein Family. <i>Journal of Biological Chemistry</i> , 2012, 287, 628-640.	3.4	26
84	Local Complement-Targeted Intervention in Periodontitis: Proof-of-Concept Using a C5a Receptor (CD88) Antagonist. <i>Journal of Immunology</i> , 2012, 189, 5442-5448.	0.8	100
85	Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. <i>Immunobiology</i> , 2012, 217, 1097-1105.	1.9	39
86	Manipulating the mediator: Modulation of the alternative complement pathway C3 convertase in health, disease and therapy. <i>Immunobiology</i> , 2012, 217, 1057-1066.	1.9	44
87	Preface. <i>Immunobiology</i> , 2012, 217, 1025.	1.9	0
88	Autoregulation of thromboinflammation on biomaterials and cells by a novel therapeutic coating technique. <i>Immunobiology</i> , 2012, 217, 1140.	1.9	0
89	Complement in action: An analysis of patent trends from 1976 through 2011. <i>Immunobiology</i> , 2012, 217, 1157-1158.	1.9	0
90	Compstatin induces allosteric changes in C3 and C3b and changes their ligand binding pattern. <i>Immunobiology</i> , 2012, 217, 1160.	1.9	0

#	ARTICLE	IF	CITATIONS
91	On the conformational flexibility of C3b: A molecular insight into activation and transformation of a major complement effector. Immunobiology, 2012, 217, 1192.	1.9	0
92	Advances in Understanding the Structure, Function, and Mechanism of the SCIN and Efb Families of Staphylococcal Immune Evasion Proteins. Advances in Experimental Medicine and Biology, 2012, 946, 113-133.	1.6	31
93	Interactions between coagulation and complement—their role in inflammation. Seminars in Immunopathology, 2012, 34, 151-165.	6.1	393
94	Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro. Blood, 2012, 120, 370-370.	1.4	0
95	Synthesis and Activity of Thioether-Containing Analogues of the Complement Inhibitor Compstatin. ACS Chemical Biology, 2011, 6, 753-760.	3.4	70
96	Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Molecular Immunology, 2011, 48, 481-489.	2.2	62
97	Innate immunity activation on biomaterial surfaces: A mechanistic model and coping strategies. Advanced Drug Delivery Reviews, 2011, 63, 1042-1050.	13.7	163
98	Protection of Nonself Surfaces from Complement Attack by Factor H-Binding Peptides: Implications for Therapeutic Medicine. Journal of Immunology, 2011, 186, 4269-4277.	0.8	85
99	Characterization of the interactions between C3b and complement regulators. Molecular Immunology, 2010, 47, 2259-2259.	2.2	0
100	Complement: a key system for immune surveillance and homeostasis. Nature Immunology, 2010, 11, 785-797.	14.5	2,990
101	Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17621-17626.	7.1	77
102	Structures of C3b in Complex with Factors B and D Give Insight into Complement Convertase Formation. Science, 2010, 330, 1816-1820.	12.6	241
103	Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. Molecular Immunology, 2010, 47, 2222-2222.	2.2	0
104	Molecular Basis for Complement Recognition and Inhibition Determined by Crystallographic Studies of the Staphylococcal Complement Inhibitor (SCIN) Bound to C3c and C3b. Journal of Molecular Biology, 2010, 402, 17-29.	4.2	39
105	Contribution of Chondroitin Sulfate A to the Binding of Complement Proteins to Activated Platelets. PLoS ONE, 2010, 5, e12889.	2.5	42
106	A flow-through optical sensor system for label-free detection of proteins and DNA. , 2009, , .		1
107	A Molecular Insight into Complement Evasion by the Staphylococcal Complement Inhibitor Protein Family. Journal of Immunology, 2009, 183, 2565-2574.	0.8	63
108	Oligohis-tags: mechanisms of binding to Ni ²⁺ –NTA surfaces. Journal of Molecular Recognition, 2009, 22, 270-279.	2.1	177

#	ARTICLE	IF	CITATIONS
109	Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. <i>Journal of Molecular Recognition</i> , 2009, 22, 495-505.	2.1	48
110	Crystallization of human complement component C3b in the presence of a staphylococcal complement-inhibitor protein (SCIN). <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2009, 65, 482-485.	0.7	10
111	Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. <i>Nature Immunology</i> , 2009, 10, 728-733.	14.5	299
112	Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. <i>Nature Immunology</i> , 2009, 10, 721-727.	14.5	205
113	Real-time label-free detection of complement activation products in human serum by white light reflectance spectroscopy. <i>Biosensors and Bioelectronics</i> , 2009, 24, 3359-3364.	10.1	17
114	Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R). <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 7254-7264.	3.0	39
115	Recent developments in low molecular weight complement inhibitors. <i>Molecular Immunology</i> , 2009, 47, 185-195.	2.2	96
116	Complement evasion by human pathogens. <i>Nature Reviews Microbiology</i> , 2008, 6, 132-142.	28.6	654
117	Electrostatic contributions drive the interaction between <i>Staphylococcus aureus</i> protein Efb and its complement target C3d. <i>Protein Science</i> , 2008, 17, 1894-1906.	7.6	34
118	Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry. <i>Molecular Immunology</i> , 2008, 45, 3142-3151.	2.2	19
119	Novel insights into target specificities and molecular mechanisms for two potent complement evasion proteins from <i>Staphylococcus aureus</i> . <i>Molecular Immunology</i> , 2008, 45, 4114-4115.	2.2	0
120	Identification of complement-targeting peptides using phage-display libraries. <i>Molecular Immunology</i> , 2008, 45, 4180-4181.	2.2	1
121	Compstatin: A Complement Inhibitor on its Way to Clinical Application. <i>Advances in Experimental Medicine and Biology</i> , 2008, 632, 262-281.	1.6	139
122	Cutting Edge: Members of the <i>Staphylococcus aureus</i> Extracellular Fibrinogen-Binding Protein Family Inhibit the Interaction of C3d with Complement Receptor 2. <i>Journal of Immunology</i> , 2008, 181, 7463-7467.	0.8	54
123	Characterization of Ehp, a Secreted Complement Inhibitory Protein from <i>Staphylococcus aureus</i> . <i>Journal of Biological Chemistry</i> , 2007, 282, 30051-30061.	3.4	84
124	A novel complement evasion mechanism of <i>Staphylococcus aureus</i> using Efb. <i>Molecular Immunology</i> , 2007, 44, 3926.	2.2	0
125	Complement-targeted therapeutics. <i>Nature Biotechnology</i> , 2007, 25, 1265-1275.	17.5	427
126	A structural basis for complement inhibition by <i>Staphylococcus aureus</i> . <i>Nature Immunology</i> , 2007, 8, 430-437.	14.5	148

#	ARTICLE	IF	CITATIONS
127	Exploring the Complement Interaction Network Using Surface Plasmon Resonance. , 2007, 598, 260-278.		16
128	Comparative Epitope Mapping with Saturation Transfer Difference NMR of Sialyl LewisX Compounds and Derivatives Bound to a Monoclonal Antibody. Journal of Medicinal Chemistry, 2005, 48, 6879-6886.	6.4	25